Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (January 2024)
29 slides from Sutro Biopharma's investor presentation, Jan 8, 2024
Slide 1: Company Overview January 2024
Company Overview January 2024 Sutro Biopharma NASDAQ: STRO Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Sutro is a Clinical-Stage Oncology Company
Luveltamab tazevibulin Phase 1 data has demonstrated efficacy in ovarian cancer patients with a broad range of FolRα expression levels. Innovative Development Toolkit Assets optimized for purity and efficacy are made by Sutro’s product engine, creating diverse modalities (e.g., ADCs, bispecific ADCs
Slide 4: Sutro's Robust Pipeline of Product Candidates
Sutro’s Robust Pipeline of Product Candidates Demonstrates our Innovative Processes and Designed Intentionally to Expand Patient Benefit in Areas of High Unmet Need PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2/3 WORLDWIDE OR GEOGRAPHIC PARTNER SUTRO-LED PROGRAMS Luvelt
Slide 5: Achievements and Milestones
Achievements and Milestones 5 Targeted Timing Luveltamab tazevibulin (luvelta, STRO-002) in Multiple Indications Highlight potential multi-cancer opportunity for luvelta in comprehensive presentation January 2024 LPI for Part 1 of REFRaME-O1, a Phase 2/3 registration-directed trial in platinum-resis
Slide 6: Luveltamab Tazevibulin – A Pipeline in a Drug
Luveltamab Tazevibulin – A Pipeline in a Drug (Luvelta, STRO-002)
Slide 7: Luvelta: Exemplifies Sutro's Innovation in ADC Development
Luvelta: Exemplifies Sutro’s Innovation in ADC Development Cell-free XpressCF® Proven Technology and Partnership Model Luvelta FolRα-targeting ADC: A Pipeline-in-a-Drug Opportunity Next-Generation ADCs Have the Potential to Improve Clinical Outcomes and Combinability Positioned to execute - Cash run
Slide 8: Luvelta: Potential for Significant Commercial Opportunities
Luvelta: Potential for Significant Commercial Opportunities, Initially in Ovarian Cancer and Expanding to Additional FolRα Expressing Cancers Luvelta Potentially Doubles the Addressable PROC Patients Estimated Annual Incidence in FolRα-Expressing Patient Populations (U.S., Europe and Japan) PROC: Pl
Slide 9: Luvelta: Strategic Development Plan
Luvelta: Strategic Development Plan Aimed at Realizing the Full Potential Therapeutic Area Preclinical Phase 1/1B Phase 2/3 2024 Milestones Ovarian Cancer Part 1: LPI – 1H Part 2: Open EU Sites– 2H Ovarian Cancer Complete Complete Complete Continuing clinical development Endometrial Cancer Continuin
Slide 10: Luvelta: Peds RAM-AML Positioned for Potential PRV
Luvelta: Peds RAM-AML Strategically Positioned for Potential PRV and Accelerates Market Entry and Commercial Readiness for OC Eligibility Dose Finding Dose Expansion Key Endpoints Relapsed/Refractory CBFA2T3::GLIS2 AML ≥ 5% Bone Marrow Involvement with Leukemic Blasts Complete remission (CR) rate Me
Slide 11: Treatment Eligibility is Driven by FolRα Biomarker Test
Treatment Eligibility is Driven by FolRα Biomarker Test Luvelta has demonstrated clinical activity in PROC patients with FolRα ≥25% Both Luvelta and FDA-approved ADC test patient FolR⍺ levels via Ventana validated assay Due to high frequency of testing of FolR⍺ in OC, patient expression level may be
Slide 12: Luvelta Registrational Strategy Supported by Clinical Data
Luvelta Registrational Strategy Supported by Clinical Data from ~100 Treated Patients Across all Doses Partial response 3 in 5.2, 2 in 4.3, 2 in <=2.9, and 1 in >=5.6mg/kg Starting dose, Q3W ≤ 2.9 mg/kg 4.3 mg/kg 5.2 mg/kg ≥ 5.6 mg/kg 20% -30% Data as of Nov 8, 2023. Ovarian Cancer Patients Total (N
Slide 13: Phase 1 Anti-Tumor Activity and Tolerable Safety in Ovarian Cancer
Phase 1: Dose Expansion Signal Seeking Plus G-CSF (Neutropenia Mgt) N = 44 N = 16 Established FolRα ≥25% PROC Reduced high-grade neutropenia Luvelta Demonstrated Compelling Anti-Tumor Activity and Tolerable Safety Broadly in Ovarian Cancer Phase 1: Dose Escalation Escalation Combo w/ Bevacizumab N =
Slide 14: Luvelta Monotherapy Safety Profile Manageable
Luvelta Monotherapy Safety Profile has been Manageable with Low Discontinuation Rate due to Neutropenia TEAEs (N=99) TEAEs (N=18) Preferred Term All Grade Incidence ≥35% Grade 3+ Patients reporting at least one event 99 (100.0%) 86 (86.9%) Neutropenia* 69 (69.7%) 64 (64.6%) ‡ Nausea 69 (69.7%) 1 (1.
Slide 15: Luvelta Activity in Lower and Variable FolRα Tumors
Luvelta: Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile In Lower and/or Variable FolRα Expression Tumors Additional Indications Phase 1: Dose Expansion (all single agent) Endometrial RAM AML1 NSCLC N = 17 N = 25 Preclinical Evidence of anti-tumor activity No new safety sig
Slide 16: Prophylactic G-CSF Reduction of Neutropenia
Use of Prophylactic G-CSF on Day 8 with 5.2mg/kg Dose Demonstrated Effective Reduction of Neutropenia Grade 3+ Neutropenia Cohort A1 vs. Cohort with G-CSF2 1 - Cohort A patients dosed with Luvelta 5.2mg/kg. 2 - Cohort with G-CSF patients started at Luvelta 5.2mg/kg + prophylactic pegfilgrastim on Da
Slide 17: Luvelta Activity in Endometrial Cancer: ESMO 2023
Luvelta Showed Evidence of Anti-tumor Activity in FolRα Expressing Endometrial Cancer: Data Presented at ESMO 2023 Maximum Reduction in Target Lesions* Consistent Safety Signals Observed 2 pts had Δ 0% Partial Response 20% -30% TPS (%) 5 15 1 2 99 6 25 45 15 35 8 45 75 18 70 30 Median exposure (rang
Slide 18: Luvelta Activity in Pediatric RAM Phenotype AML: ASH 2023
Luvelta Showed Anti-Tumor Activity in Pediatric RAM Phenotype AML: Data Highlighted at ASH 2023 Received Luvelta as Non-Fractionated Dosing Regimen (N=21*^) Safety Overview TEAES occurring in ≥25% of patients who received monotherapy with Luvelta Total (N = 21) AEs, n (%) Any grade Grade ≥3 Neutroph
Slide 19: FolRα is Broadly Expressed Across Multiple Indications
FolRα is Broadly Expressed Across Multiple Indications Source: Cheung et al. “Targeting folate receptor alpha for cancer treatment.” Oncotarget. 2016; 7: 52553-52574. Key Takeaways for Luvelta Demonstrated clinical activity across multiple indications Potential to show activity in tumors with varyin
Slide 20: STRO-003 and Emerging Research Portfolio
STRO-003 and Emerging Research Portfolio
Slide 21: Sutro's Flexibility in Design and Innovative Toolkit
2. Single or Dual Conjugations of Different Mechanisms 1. Mono- or Bispecific TAA Targeting Sutro’s Flexibility in Design and Innovative Toolkit Provide the Potential for Superior Solutions and the Opportunity for an Improved Patient Experience Enhanced tumor targeting with cytotoxic payloads Bispec
Slide 22: Limitless Innovation: Approach to Future ADC Development
Limitless Innovation: Sutro’s Approach to Future ADC Development ADC Potency Immunogenic Cell Death Induction Resistance to Top1/Exatecan *Unique advantage of non-natural amino acid incorporation by Cell-free XpressCF® Dual Conjugate* DAR > 8* On-target Activity Improve-ments
Slide 23: STRO-003: A Novel ROR1 Targeted ADC
STRO-003: A Novel ROR1 Targeted ADC is Designed for Purpose ROR1 biology makes it an attractive ADC target Expansive indication space in oncology Potential for attractive clinical performance ROR1: Role in cancer progression and expressed in tumor and tumor- initiating cells Low potential for on-tar
Slide 24: STRO-003 is a Single Homogeneous ADC with DAR of 8
STRO-003 is a single homogeneous ADC with a drug-antibody ratio (DAR) of 8, targeting ROR1 tumor antigen pAMF ROR1 Targeted ROR1 epitope is overexpressed in diverse cancers including hematological and solid tumor indications Precisely positioned non-natural amino acids, p-azidomethyl-L-phenylalanine
Slide 25: STRO-003 Anti-Tumor Activity in NSCLC and Breast Cancer Models
STRO 03 Demonstrated Anti-Tumor Activity in Nonclinical NSCLC and Breast Cancer Models Nonclinical models of anti-tumor activity across low and heterogenous ROR1 antigen levels STRO-003 demonstrated complete regression of human patient-derived NSCLC xenografts expressing low and heterogeneous ROR1 a
Slide 26: STRO-003 Well Tolerated in Preclinical Toxicity Models
STRO 03 Well Tolerated in Preclinical Toxicity Models at High Dose Levels—Potentially Reducing Lung Toxicity While Demonstrating ROR1-dependent In Vitro Tumor Killing Safety STRO-003 was well tolerated in rodent and NHP exploratory toxicity studies In rats, no observed neutropenia, no elevation of l
Slide 27: Strategic iADC Collaboration with Astellas
$90M upfront to develop iADCs for up to three targets Research activities are being conducted for two targets, representing two distinct programs $422.5M in development, regulatory and commercial milestones for each product candidate, plus tiered royalties ranging from low-double digit to mid-teen p
Slide 28: Financial Overview – December 31, 2023
~$375M(1) in cash, cash equivalents & marketable securities and Vaxcyte stock Projected cash runway into 2H 2025, based on current business plans and assumptions ~0.7M shares of Vaxcyte (Nasdaq: PCVX) included in the $ amount above Funding generated from our collaborators of ~$850M(2) 1. Based on th
Slide 29: Experienced Leadership Team
Experienced Leadership Team Lynx Neurex 29 Anne Borgman, MD Chief Medical Officer Venkatesh Srinivasan, PhD Chief Technical Operations Officer Linda Fitzpatrick Chief People and Communications Officer Nicki Vasquez, PhD Chief Portfolio Strategy and Alliance Officer Jane Chung, RPh President and Chie
Sutro Biopharma — Investor Presentation (January 2024) on 6ix